This is going no where in the near future. The RS news has ensured that. The ESS pr again is not concrete news, it's all speculative. Until the trial is funded, started, shows the same past results and finishes, this other is all nonsense. Fluff and/or old news/data is the cornerstone of AMBS PRs.
Before we start talking about "running to $1" let's get the trial started and get back up to .10 and hold it. Some are getting a bit ahead of themselves assuming Trial success before it even starts.
(2)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links